Table 2 Costs and effects of changing the ANC cutoff line (500/mm3–1000/mm3–1500/mm3) in Japan and the UK.

From: Cost effectiveness of pharmacogenetic-guided clozapine administration based on risk of HLA variants in Japan and the UK

Cutoff line

Cost/QALYs

JPN

UK

HLA-guided treatment schedule

general treatment schedule without HLA test

HLA-guided treatment schedule

general treatment schedule without HLA test

500/mm3

Cost per patient £

16,257 (16,255–16,258)

16,173

4021 (4008–4023)

3,928

 

QALYs for ten years

6.27343 (6.27389–6.27334)

6.27316

5.85539 (5.85672–5.85512)

5.85459

 

ICER £/ (QALY): HLA-guided treatment schedule vs. general treatment schedule without HLA test

307,957 (111,753–464,946)

116,190 (37,712–178,986)

1000/mm3

Cost per patient £

16,401 (16,377–16,405)

16,329

4151 (4119–4157)

4070

 

QALYs for ten years

6.25207 (6.25607–6.25126)

6.24967

5.84267 (5.84698–5.84198)

5.84062

 

ICER £/ (QALY): HLA-guided treatment schedule vs. general treatment schedule without HLA test

29,836 (7444–47,810)

39,512 (8958–63,968)

1500/mm3

Cost per patient £

16,552 (16,517–16,558)

16,487

4281 (4230–4291)

4211

 

QALYs for 10 years

6.22917 (6.23434–6.22813)

6.22608

5.8299 (5.83533–5.82882)

5.82665

 

ICER £/ (QALY): HLA-guided treatment schedule vs. general treatment schedule without HLA test

21,024 (3729–34,920)

21,343 (2145–36,715)

  1. The numbers in the parentheses indicates results from the sensitivity analysis for CIAG prevention rate (80–20%).
  2. JPN Japan, UK United Kingdom, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, CIAG Clozapine-induced agranylocytosis/granulocytopenia.